The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Okubo, T.
Right arrow Articles by Ishigatsubo, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okubo, T.
Right arrow Articles by Ishigatsubo, Y.
The Journal of Immunology, 1999, 162: 4013-4017.
Copyright © 1999 by The American Association of Immunologists

Administration of an IL-12-Encoding DNA Plasmid Prevents the Development of Chronic Graft-Versus-Host Disease (GVHD)

Tadanobu Okubo1,*, Eri Hagiwara*, Shigeru Ohno*, Takashi Tsuji*, Atsushi Ihata*, Atsuhisa Ueda*, Akira Shirai*, Ichiro Aoki{dagger}, Kenji Okuda{ddagger}, Jun-ichi Miyazaki§ and Yoshiaki Ishigatsubo*

Departments of * First Internal Medicine, {dagger} Second Pathology, and {ddagger} Bacteriology, Yokohama City University School of Medicine, Yokohama, Japan; and § Department of Nutrition and Physiological Chemistry, Osaka University Medical School, Osaka, Japan

The transfer of DBA/2 spleen cells into (C57BL/10 x DBA/2)F1 mice induces chronic graft-vs-host disease (GVHD), which is characterized by the production of Th2 cytokines, hypergammaglobulinemia, and immune complex-mediated glomerulonephritis like systemic lupus erythematosus. IL-12 strongly induces the production of Th1 cytokines and reduces Th2 activity in vivo. In this study, the effect of gene therapy on the development of murine chronic GVHD was examined using an IL-12-encoding plasmid (pCAGGSIL-12), with the expectation that it might regulate Th1/Th2 activity and have a beneficial impact on the clinical manifestations of disease. pCAGGSIL-12 or its p40 antagonist plasmid (pCAGGSp40) were injected i.m. every 3 wk in GVHD-induced (C57BL/10 x DBA/2)F1 mice. A total of 100 µg of pCAGGSIL-12 improved the Th1/Th2 balance in vivo, suppressed the production of IgG, and significantly reduced the development of glomerulonephritis. GVHD was exacerbated by injection of the pCAGGSp40 antagonist. Our results demonstrate that GVHD can be treated successfully by the administration of an IL-12-encoding plasmid, and that such therapy does not induce acute GVHD.




This article has been cited by other articles:


Home page
J. Immunol.Home page
R. Puliaev, I. Puliaeva, L. A. Welniak, A. E. Ryan, M. Haas, W. J. Murphy, and C. S. Via
CTL-Promoting Effects of CD40 Stimulation Outweigh B Cell-Stimulatory Effects Resulting in B Cell Elimination and Disease Improvement in a Murine Model of Lupus
J. Immunol., July 1, 2008; 181(1): 47 - 61.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
M. Chen, F. Aosai, K. Norose, H.-S. Mun, H. Ishikura, S. Hirose, L.-X. Piao, H. Fang, and A. Yano
Toxoplasma gondii infection inhibits the development of lupus-like syndrome in autoimmune (New Zealand Black x New Zealand White) F1 mice
Int. Immunol., July 1, 2004; 16(7): 937 - 946.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.